Kornimate/medical-research-clean huggingface dataset:
author-wang ping-- research：application of ultrasonic guided puncture in blood collection in patients with severe trauma

Conditions: Severe Trauma

Summary: this study aimed to investigate the application of ultrasound guided puncture technique in blood collection in patients with severe trauma. the methods of this study is 93 patients with severe trauma were selected from the emergency room of the second affiliated hospital of zhejiang university from april 2020 to september 2,2020 and from october 2020 to march 2021, comparing the differences between nursing treatment efficiency and doctor satisfaction.

standard process for blood collection using ultrasonic guided puncture.the control group used the traditional blood sample collection process, which was mainly based on personal clinical experience. statistical analysis using spss 25.0 statistical software. observation index are time index of nursing treatment for patients with severe trauma: the time required for acquisition time, disposable puncture success rate, blood routine and blood type delivery time, rescue room stay time, etc and patient family and doctor satisfaction analysis: self-designed questionnaire, family satisfaction process, service time, service attitude, rescue technology, health education, including advice time, nursing quality, medical communication, teamwork, service attitude, evaluation levels: very satisfaction, satisfaction and dissatisfaction.

Eligibility criteria:
inclusion criteria: * ① airway obstruction, need tracheal intubation or intubation;② breathing stop, respiratory distress or significant slowing down;③ circulatory system shows various shock signs④gcs≤8;⑤ body table visible head, torso, chest open injury or yoke chest exclusion criteria: * all patients who stop the rescue room trauma evaluation and treatment midway through hospital transfer and automatic discharge

Keywords: ultrasound guidance severe trauma nursing care blood specimen collection
gabapentin in treating hot flashes in patients with prostate cancer

Conditions: Hot Flashes; Prostate Cancer

Summary: rationale: gabapentin may be effective in relieving hot flashes in men who have prostate cancer. it is not yet known which regimen of gabapentin is most effective in treating hot flashes. purpose: randomized phase iii trial to compare different regimens of gabapentin in treating men who have prostate cancer.

objectives: * determine the effectiveness of gabapentin in managing hot flashes in men with prostate cancer. * determine the response of patients to this drug. * determine the toxicity of this drug in these patients. * determine the quality of life of patients treated with this drug. outline: this is a randomized, double-blind, placebo-controlled, multicenter study. patients are stratified according to the number of hot flashes per day (2-3 vs 4-9 vs 10 or more) and duration of hot flash symptoms (less than 9 months vs 9 months or more). patients are randomized to one of four treatment arms. all patients are observed for 7 days prior to drug administration in order to collect baseline hot flash information. * arm i: patients receive oral gabapentin once daily on days 1-28. * arm ii: patients receive oral gabapentin once daily on days 1-7 and twice daily on days 8-28. * arm iii: patients receive oral gabapentin once daily on days 1-7, twice daily on days 8-14, and three times daily on days 15-28. * arm iv: patients receive oral placebo on one of three schedules corresponding to arms i-iii. patients in all arms may continue therapy with gabapentin for an additional 8 weeks. quality of life is assessed at baseline, day 28, and at the end of the additional 8 weeks. patients are followed at 6, 12, and 24 months. projected accrual: a total of 220 patients (55 per treatment arm) will be accrued for this study within 1 year.

Eligibility criteria:
required characteristics: 1. men with a history of prostate cancer who have received or are receiving androgen ablation therapy. 2. must be on a stable dose of hormone therapy for the past 4 weeks and must not be planning on discontinuing hormone therapy throughout the duration of the randomized phase (5 weeks). 3. presence of hot flashes for ≥1 month prior to study entry. 4. bothersome hot flashes (defined by their occurrence ≥14 times per week and of sufficient severity to make the patient desire therapeutic intervention). 5. life expectancy ≥ 6 months. 6. ecog performance status (ps) 0 or 1. 7. ≥18 years of age contraindications: 1. history of renal insufficiency (defined as a creatinine ≥1.5 x unl in the last two years). 2. any of the following current (≤ 4 weeks) or planned therapies: * antineoplastic chemotherapy * androgens * estrogens * progestational agents 3. history of allergic or other adverse reaction to gabapentin. 4. prior use of gabapentin. 5. antidepressants (use is allowed if patient has been on a stable dose for ≥1 month and does not plan to modify this treatment during the next 5 weeks).

Keywords: stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer recurrent prostate cancer hot flashes
thigh swelling, hip-muscle strength, and functional performance following total hip arthroplasty

Conditions: Osteoarthrosis Patients With Total Hip Arthroplasty

Summary: by this study the investigators wish to (1) quantify hip strength and functional-performance deficits at discharge after fast-track total hip arthroplasty (tha), and (2) investigate if changes in thigh circumferences, or hip pain are correlated to changes in hip strength and functional-performance after fast-track tha.

the investigators intend to use the results to optimize the rehabilitation programs for tha patients shortly after surgery

Eligibility criteria:
inclusion criteria: * total hip arthroplasty patients exclusion criteria: * inability to speak and understand danish * inability to perform the functional measurements due to other conditions

Keywords: function, hip muscle strength, hip replacement, hip pain,
effect of upper limb ergometer on the aip in post menopausal obese women.

Conditions: Post Menopausal Obese Women

Summary: participants had randomly divided into two equal groups. group (a) which is the control group receive normal routine medication. group (b) will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.

control group (a): 1. each participant will sign a consent form after receiving a detailed explanation about the procedure. 2. a blood sample will been taken by a nurse in a heparinized tube and delivered to lab within six hours. 3. bmi will been measured body weight(kg) and height (m2) a. bmi= body weight (kg)/ height (m2). 4. waist circumference will be measured. 5. after one month blood analysis evaluation will be done to record the response to the routine medication. training procedure for group (b): 1. each participant will sign a consent form after receiving a detailed explanation about the procedure. 2. a blood sample will been taken by a nurse in a heparinized tube and delivered to lab within six hours. 3. bmi will been measured body weight(kg) and height (m2) a. bmi= body weight (kg)/ height (m2). 4. waist circumference will be measured. 5. the maximum heart rate will be determined from tanaka formula (208- 0.7 \*age of the participant) * then the exercise load will be determined according heart rate reserve of the participants ( maximum heart rate - resting heart rate). 6. start with sitting resting without any effort for 5 min then start at a low speed and intensity for 5 minutes to warm up the body. 7. increase the speed and intensity for 10-30 seconds before dropping it back for 2-5 minutes and repeat according to the intensity. 8. finally, a five minutes of cooling down with no resistance had performed. 9. after one month blood analysis evaluation will be done to record the response to the routine medication.

Eligibility criteria:
inclusion criteria: * female aged 45-60 years old. * class 1 and 2 obesity. * post menopausal. * diagnosed as controlled diabetic. * diagnosed as controlled hypertensive. exclusion criteria: * uncontrolled diabetic. * uncontrolled hypertensive. * class 3 and morbid obesity. * mentally unstable person. * any shoulder, hand and elbow orthopedic or neural disorders.
a study of mrna-1018 pandemic influenza candidate vaccines in healthy adults

Conditions: Influenza

Summary: the purpose of this phase 1/2 study is to generate sufficient safety and immunogenicity data of mrna-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large phase 3 trial with one selected vaccine candidate. the study will be conducted in 2 parts (part a and part b) that will enroll and run concurrently. part a of the study will evaluate 4 vaccine candidates (h5n8, h7n9, h5 only, and h7 only). part b of the study will evaluate a single vaccine candidate (h5 only-cg).


Eligibility criteria:
key inclusion criteria: * healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing. * body mass index of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the screening visit. * for female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding. key exclusion criteria: * participant is acutely ill or febrile (body temperature ≥ 38.0 degrees celsius \[°c\]/100.4 degrees fahrenheit \[°f\]) 72 hours prior to or at the screening visit or day 1. * history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. * any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. * participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 180 days prior to screening visit (for corticosteroids ≥10 milligrams \[mg\]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. * participant has received any vaccine authorized or approved by local health agency including mrna vaccine ≤28 days prior to study intervention (day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention. * participant has participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study. other inclusion/exclusion criteria may apply.

Keywords: influenza vaccine moderna mrna-1018 virus diseases vaccines pandemic influenza
safety of the co-rebreathing method in stable coronary artery disease and copd patients

Conditions: Cardiovascular Disease; Chronic Obstructive Pulmonary Disease

Summary: the primary objective is to establish the safety of the co-rebreathing method for measuring total blood and plasma volume in cad patients. the working hypothesis is that the co-rebreathing method is safe in use with coronary artery disease patients and that it does not cause myocardial ischemia or cardiovascular damage.


Eligibility criteria:
inclusion criteria: * stable coronary artery disease * stable copd * optimal medication exclusion criteria: * unstable disease * co-morbidities

Keywords: blood volume co-rebreathing copd cvd
influence of kinetic chain training on the treatment outcome of overhead athletes with impingement

Conditions: Shoulder Impingement Syndrome

Summary: a randomized controlled trial will be conducted to examine the effectiveness of a traditional home exercise program versus 2 kinetic chain home exercise programs on treatment outcome of overhead athletes with shoulder impingement syndrome. primary outcome measures are reduction of pain and disability, and improvement in functionality and sports performance. secondary outcome measures are strength, mobility, flexibility and functional performance.

participant are randomly assigned in 3 home exercise groups. 1. the traditional program: consists of solely strengthening the rotator cuff muscles and scapular muscles (e.g. external rotation) 2. separate kinetic chain program: same exercises as the first group but they also receive an exercise program to separately train the core and lower body. (e.g. external rotation separately and squat separately) 3. integrated kinetic chain program: same exercises as the first group but all exercises are performed while simultaneously activating the kinetic chain. (e.g. external rotation while squatting).

Eligibility criteria:
inclusion criteria: * symptoms of shoulder impingement on the dominant side for at least 3 months and at least 3 of the following tests are considered positive * jobe * hawkins * neer * painful arc during elevation * pain or lack of force production with isometric external rotation * apprehension test * relocation test * performing overhead sports at least 3 hours/week * shoulder pain interferes with sports activities * they have not had treatment for this shoulder pain exclusion criteria: * history of shoulder dislocation or subluxation * history of orthopedic surgery * no complaints of pain or dysfunction in the upper limb (except impingement related complaints in the dominant shoulder), lower limb or spine at the last 6 months * currently taking nonsteroidal anti-inflammatory medication * received a steroid injection in the past 12 months * participating in another study * known systemic diseases * known structural diseases

Keywords: shoulder impingement syndrome overhead athletes kinetic chain exercise treatment
hemostatic endothelial dysfunction in patients with peripheral artery disease

Conditions: Peripheral Artery Disease; Restenosis of Peripheral Vascular Stent; Restenosis, Vascular Graft; Endothelial Dysfunction

Summary: the study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide ii (no) metabolites, plasmin activator inhibitor-1 (pai-1), von willebrand factor (vwf), coagulation factor viii (fviii), soluble endothelial protein c receptors (sepcr)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.

the study will involve patients with atherosclerotic peripheral artery disease (rutherford category 3-5). the subjects are to be divided into three groups: group a: patients who undergo bypass surgery with a synthetic graft on aorto-iliac or femoro-popliteal segment; group b: patients who undergo endovascular balloon angioplasty and stenting on aorto-iliac or femoro-popliteal segment; group c: patients who undergo standard of care conservative treatment. decisions on revascularization or conservative treatment alone is to be made by a team of vascular specialists in accordance with the severity of the disease, previous treatment, anatomy, possible need for repeat procedures in the future, and patient's preferences.

Eligibility criteria:
inclusion criteria: 1. males or females older than 40 years of age; 2. presence of peripheral arterial disease of atherosclerotic origin. exclusion criteria: 1. males or females younger than 40 years of age; 2. chronic lower limb ischemia of other ethiology (buerger's disease, aortoarteritis etc.); 3. active cancer or remission period less than 5 years; 4. decompensated diabetes mellitus; 5. pregnancy or breast-feeding for females.

Keywords: hemostasis, endothelial dysfunction, restenosis, thrombosis
independence stairs climbing ability prediction during the sub-acute rehabilitation phase of people after stroke

Conditions: CVA

Summary: independence stairs climbing ability prediction during the sub-acute rehabilitation phase of people after stroke


Eligibility criteria:
inclusion criteria: * first cerebro vascular accident (cva) diagnosis * basic cognitive and communicative abilities exclusion criteria: * traumatic brain injury (tbi) * confusion state and lack of cooperation due to brain lesion * unstable cardiovascular status * independently climbing stairs ability at entrance
sub-clinical inflammation and iron supplementation

Conditions: Anemia

Summary: anemia and vitamin a deficiency (vad) are major nutritional problems in the world and also in myanmar. both nutrient deficiencies result from interaction of several causal factors, and a better understanding of the etiology to interpret the prevalence and to formulate appropriate measures to reduce these deficiencies is necessary. there is a growing concern on the role of sub-clinical inflammation on the nutritional status indicators during the nutritional status assessment. however, there is lack of information on the role of inflammation on the iron supplementation. the adolescent period is a window of opportunity to improve the preconceptional iron status of the girls and recently gained much attention. the purpose of the study is to understand the role of inflammation on iron and vitamin a status during iron and vitamin a supplementation. the findings will show the extent to which iron supplementation has been hampered by inflammation and to formulate the necessary measures to overcome the interference.


Eligibility criteria:
inclusion criteria: * adolescent girls (age 12-19 years) * already experienced menarche * anemic girls (hb\<120 g/l) * no known illness (apparently healthy) * free from haemoglobinopathy * no regular consumption of iron and vitamin a supplement during the last 3 months exclusion criteria: * subjects with chronic illness * subjects with severe anaemia * who do not give the consents

Keywords: anemia iron supplementation sub-clinical inflammation adolescents
sensitivity training for parents of preterm infants

Conditions: Development; Preterm Birth

Summary: immediately following birth, preterm infants face a period of stressful environmental inputs, which may have negative consequences on early brain development and subsequent neurobehavioral outcomes. this study aimed to assess the effectiveness of training parents in reducing stressful experiences early in life. the investigators hypothesized that this intervention would insulate preterm infants from the harmful effects of acute and chronic stress, which in turn would result in enhanced brain development. the primary aim of the current study was to investigate if this intervention was associated with improved brain development measured by magnetic resonance imaging (mri) at term-equivalent age. a secondary aim was to assess some possible short-term medical benefits.

a randomized controlled trial of a parental sensitivity training program involving 45 women with infants born \< 30 weeks gestational age. the intervention consisted of 10 individual sessions in the neonatal intensive care unit (nicu). post-intervention, at term-equivalent age (40 weeks postmenstrual age), magnetic resonance (mr) imaging was performed to evaluate brain structure and development. quantitative volumetric techniques were used to estimate overall and regional brain volumes for different tissue types including cerebrospinal fluid (csf), cortical grey matter (cgm), deep nuclear grey matter (dngm), unmyelinated white matter (uwm) and myelinated white matter (mwm). diffusion tensor imaging (dti) was used to evaluate the integrity and maturation of white matter by apparent diffusion coefficient (adc) and fractional anisotropy (fa).

Eligibility criteria:
inclusion criteria: * \> 30 weeks gestation exclusion criteria: * insufficient english * congenital abnormality * triplets and higher multiple births * residence \> 100 km from study site

Keywords: preterm bith neurodevelopment sensitivity training magnetic resonance imaging (mri) infant neurodevelopment following preterm birth
safety and efficacy of a new transepithelial photorefractive keratectomy treatment

Conditions: Ametropia

Summary: this is a prospective, comparative, randomized, controlled, single-blind, single-surgeon, single-center pmcf clinical study whereby participants undergoing refractive surgery for correction of ametropia will receive a transepithelial prk (tprk) and conventional prk treatment in the contralateral eye. to avoid bias in the clinical outcomes, the two prk treatment options are randomized to the eyes of the patients based on ocular dominance. in addition, a 1:1 randomization is applied within the tprk group to eyes with and without end-treatment laser polishing. both procedures, standard prk and tprk, are performed in a one-step procedure. the main difference between the procedures is, that in conventional prk, the epithelium will be removed using alcohol, whereas in tprk procedures, the epithelium will be removed by laser ablation.


Eligibility criteria:
inclusion criteria: * ametropia * myopic subjects with refractive spherical equivalent (mrse) between -1.5d and -9.0d * hyperopic subjects with refractive spherical equivalent (mrse) between +1.5d and +5.25d * signed informed consent form exclusion criteria: * ocular comorbidity * subject taking systemic medications likely to affect wound healing such as corticosteroids or antimetabolites. * subjects who are known to be pregnant, lactating, or who plans to become pregnant over the medications used for standard tprk. * subjects participating in any other ophthalmic clinical trial during this clinical study. * subjects with cognitive impairments or other vulnerable persons